- Endonovo Therapeutics is developing bioelectronic devices that target patient pain, inflammation and wound recovery
- The company intends to get its flagship SofPulse device into 600 hospitals within the next 18 months as part of its bid to reduce post-operative drug dependence
- Drug dependence is regarded as a major contributor to a global opioid epidemic that has driven advocacy for less harmful pain drugs, increased governmental funding and new sentencing protocols for drug-related crimes
- The U.S. government has spent $2.4 billion during the past two years on addiction intervention amid statistics showing pain-killer death totals in the tens of thousands each year
Worldwide concerns about pain relief medication-induced addictions and deaths have led to a variety of societal changes during recent years, most notably driving the multinational advocacy for medical marijuana (cannabis) as a potential palliative without the degree of harmful effects from prescription and illegal narcotics, while also spawning increasing calls for governmental funding to fight addiction and change the judicial system’s approach to drug-related crimes. Amid some concerns about how private industry and governmental agencies are responding to the opioid epidemic/pandemic, Endonovo Therapeutics Inc. (OTCQB: ENDV) is advancing novel bioelectronic device solutions that are non-invasive and sidestep the drug issues entirely.
Endonovo Therapeutics is a commercial-stage developer of medical implements designed to provide proprietary, patent-protected electroceutical therapy for treating patient pain, inflammatory conditions, cardiovascular diseases and…
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com